Prnewswire·2025-12-18 11:45Core Insights - Eli Lilly's orforglipron achieved positive results in the ATTAIN-MAINTAIN trial, demonstrating superior weight maintenance compared to placebo after transitioning from injectable therapies Wegovy or Zepbound [1][2] - The drug has been submitted to the U.S. FDA for obesity treatment, potentially offering a convenient oral alternative for weight management [1][2] Group 1: Trial Results - In the ATTAIN-MAINTAIN trial, participants switching from Wegovy maintained an average weight loss of 0.9 kg, while those switching from Zepbound maintained an average of 5.0 kg [2][3] - The primary endpoint was met, showing superior percent maintenance of body weight reduction compared to placebo [2][7] - The trial involved 376 participants and was designed as a randomized, double-blind, placebo-controlled study [6][7] Group 2: Drug Profile - Orforglipron is a once-daily oral GLP-1 receptor agonist that can be taken without food or water restrictions [5] - The drug was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018, with ongoing Phase 3 studies for type 2 diabetes and weight management [5][8] - The overall safety profile of orforglipron was consistent with previous studies, with gastrointestinal-related adverse events being the most common [4][5] Group 3: Future Developments - Detailed results from the ATTAIN-MAINTAIN trial will be presented at a future medical meeting and published in a peer-reviewed journal next year [5] - Lilly has received a Commissioner's National Priority Voucher from the U.S. FDA for orforglipron, indicating its significance in addressing obesity [5]